A Phase 4 interventional study of Fluoxetine 20 MG and Duloxetine 30 MG in Depression, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Wake Forest University Health Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing fluoxetine in Depression — 9 open to participants now, 10 under way, 1 of them phase 3. Fluoxetine · Depression.
Among the 43 studies testing fluoxetine in Depression, this one is the 21st largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2025, is one of 9 in phase 4, and was the 36th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →9 of the 43 studies testing fluoxetine in Depression are open now, in 7 countries. Recruiting first, the newest first:
University of Oxford · Sites in United Kingdom
Ages 18–24 · Healthy volunteers
University of Bern · Sites in Zimbabwe
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 12+
Federal University of Latin American Integration · Sites in Brazil
Ages 25–65 · Healthy volunteers
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 13–18
By country, each count listing its studies:
Fluoxetine: first FDA approval 1987 (SARAFEM). What it is approved for, and how studies give it, is on its page →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 9 · Phase 4 9
First in 1995; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 97 across the 42 interventional studies. Of the 30 that completed or were terminated, 13 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 43 have an industry lead sponsor. The 10 most frequent:
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
39 studies in Depression by Wake Forest University Health Sciences: 6 open now, 7 under way, none of them phase 3. Of 29 finished, 15 (52%) have results posted.
Among the 39 studies in Depression by Wake Forest University Health Sciences, this one is the 7th largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 4, and was the 33rd registered.
Wake Forest University Health Sciences’s Depression studies by the year they started, since 2001.
6 of the studies testing fluoxetine in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424781University of OxfordFluoxetine on Emotional Experience (FLEX) Study | 2026-12-31 |
| NCT05814640First Affiliated Hospital of Chongqing Medical UniversitySequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) | 2026-12-31 |
| NCT05976347Wake Forest University Health SciencesIdentifying and Treating Depression in the Orthopaedic Trauma Population | 2027-05 |
| NCT07456501University of OxfordFluoxetine and Understanding Social Experiences | 2027-07-20 |
| NCT07110831University of IbadanDisposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria | 2027-09-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 43 studies testing fluoxetine in Depression, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Wake Forest University Health Sciences’s 39 in Depression:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are:
Depression is common among orthopaedic trauma patients and associated with worsened outcomes including pain, opioid consumption, patient-reported outcomes ,complications, and length of stay. Addressing depression, therefore, should lead to improved outcomes. Orthopaedic surgeons may believe treating depression is outside their scope or that they lack tools to address depressive symptoms. In fact, only 45% of surgeons report they are likely to screen patients, and only 27% are likely to refer patients for psychological treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluoxetine, 20mg once daily
Drug: Fluoxetine 20 MG
Duloxetine, 30mg once daily
Drug: Duloxetine 30 MG
Referral to behavioral health per standard practice and provision of resources for strategices to address depressive symptoms.
Other: Observation
Fluoxetine 20 mg once daily
Also known as: Prozac Weekly, Sarafem, Prozac
Duloxetine 30 mg once daily
Also known as: Irenka and Cymbalta
Referral to behavioral health and resources for addressing depressive symptoms
Also known as: Referral to behavioral health and resources
Depressive Symptom Scores
Improvement in depressive symptoms, indication by either remission (PHQ-9 score \<5) or a 50% reduction in PHQ-9 score. The Patient Health Questionnaire (PHQ-9) is a self-report tool that incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms. The too rates the frequency of the symptoms which factors into the scoring severity index. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe and severe depression.
Time frame: Baseline
Depressive Symptom Scores
Improvement in depressive symptoms, indication by either remission (PHQ-9 score \<5) or a 50% reduction in PHQ-9 score. The Patient Health Questionnaire (PHQ-9) is a self-report tool that incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms. The too rates the frequency of the symptoms which factors into the scoring severity index. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe and severe depression.
Time frame: Month 3
Depressive Symptom Scores
Improvement in depressive symptoms, indication by either remission (PHQ-9 score \<5) or a 50% reduction in PHQ-9 score. The Patient Health Questionnaire (PHQ-9) is a self-report tool that incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms. The too rates the frequency of the symptoms which factors into the scoring severity index. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe and severe depression.
Time frame: Month 6
Depressive Symptom Scores
Improvement in depressive symptoms, indication by either remission (PHQ-9 score \<5) or a 50% reduction in PHQ-9 score. The Patient Health Questionnaire (PHQ-9) is a self-report tool that incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms. The too rates the frequency of the symptoms which factors into the scoring severity index. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe and severe depression.
Time frame: Month 9
Depressive Symptom Scores
Improvement in depressive symptoms, indication by either remission (PHQ-9 score \<5) or a 50% reduction in PHQ-9 score. The Patient Health Questionnaire (PHQ-9) is a self-report tool that incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms. The too rates the frequency of the symptoms which factors into the scoring severity index. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe and severe depression.
Time frame: Year 1
Adherence to Treatment Percentage
Adherence to treatment and side effects or adverse events associated with the medications will be collected using patient logs, study visit questionnaires, and the medical record (i.e., number of prescriptions filled).
Time frame: Months 3, 6, and 12
Utilization of non-pharmaceutical tools and resources Percentage
Engagement with behavioral health resources will be collected using patient logs, study visit questionnaires, and the medical record (i.e., number of visits with Behavioral Health).
Time frame: Months 3, 6, and 12
Patient Reported Outcome Measures - PROMIS-29 Scores
The PROMIS-29 scales will be scored using a T-score metric method. A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores mean a higher level of disability.
Time frame: Months 3, 6, and 12
Patient Reported Outcome Measures - Work Productivity and Activity Impairment Questionnaire Scores
The Work Productivity and Activity Impairment questionnaire measures how work productivity and activities are impaired by a specific health condition or disease. Scores are expressed as a percentage of impairment/productivity loss, a high score indicates greater impairment.
Time frame: Months 3, 6, and 12
Patient Reported Outcome Measures - Brief Pain Inventory Scores
Assesses the severity of pain and the impact of pain on daily functions. Assesses the severity of and impact of pain on daily function. Patients are asked to rate their current symptoms, average experiences of pain, and the minimum and maximum intensities of their symptoms on scales that range from 1-10. A total pain severity score can be found by averaging these items or a single items can be treated as the primary outcome. Higher scores indicate greater severity and more interference.
Time frame: Months 3, 6, and 12
Healthcare Utilization - The number of hospitalizations and ED visits
The number of hospitalizations and ED visits
Time frame: Months 3, 6, and 12
Patient Reported Outcome Measures: Patient Health Questionnaire 9 (PHQ-9)
A PHQ-9 score total of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression. The higher the score, the more symptoms of depression experienced, and the more severe the depression is.
Time frame: Months 3, 6, and 12
Patient Reported Outcome Measures - Veterans RAND 12 Item Health Survey (VR-12)
Measures health related quality of life across 7 domains. The answers are summarized into two scores - a Physical Component Score and a Mental Component Score.
Time frame: Months 3, 6, and 12
Qualitative Interview Information
Patients in the observational arm will participate in semi-structured interviews. Interviews will be recorded and transcribed verbatim within one week. Field notes will be written within one week of each interview, and the interview guide will be revised as appropriate.
Time frame: One time between 6-12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.
Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 23 months is below that.
Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluoxetine · Duloxetine
Wake Forest University Health Sciences →